PTC Therapeutics, Inc. Debt Securities, Trading, Realized Gain (Loss)
PTC Therapeutics, Inc. (PTCT) reported Debt Securities, Trading, Realized Gain (Loss) of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-06.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesTradingRealizedGainLoss · last filed 2026-02-19
- PTC Therapeutics, Inc. debt securities, trading, realized gain (loss) for the quarter ending 2025-03-31 was $0.00.
- PTC Therapeutics, Inc. debt securities, trading, realized gain (loss) for the quarter ending 2024-12-31 was -$4.20M.
- PTC Therapeutics, Inc. debt securities, trading, realized gain (loss) for the quarter ending 2024-09-30 was $800.00K.
- PTC Therapeutics, Inc. debt securities, trading, realized gain (loss) for the quarter ending 2024-06-30 was $0.00.
- PTC Therapeutics, Inc. debt securities, trading, realized gain (loss) for fiscal 2024 was -$3.40M.
- PTC Therapeutics, Inc. debt securities, trading, realized gain (loss) for fiscal 2023 was -$300.00K, a 107.50% decline from fiscal 2022.
- PTC Therapeutics, Inc. debt securities, trading, realized gain (loss) for fiscal 2022 was $4.00M, a 400.00% increase from fiscal 2021.
- PTC Therapeutics, Inc. debt securities, trading, realized gain (loss) for fiscal 2021 was $800.00K.
| Period end | Debt Securities, Trading, Realized Gain (Loss) 3 month | Debt Securities, Trading, Realized Gain (Loss) 6 month | Debt Securities, Trading, Realized Gain (Loss) 9 month | Debt Securities, Trading, Realized Gain (Loss) 12 month | Debt Securities, Trading, Realized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | -$4.20M derived: sum of 2 quarters · filed 2026-02-19 | -$3.40M derived: sum of 3 quarters · filed 2026-02-19 | -$3.40M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-12-31 | -$4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$3.40M derived: sum of 2 quarters · filed 2026-02-19 | -$3.40M derived: sum of 3 quarters · filed 2026-02-19 | -$3.40M 10-K · filed 2026-02-19 | $3.40M 10-K · filed 2025-02-27 |
| 2024-09-30 | $800.00K 10-Q · filed 2025-11-04 | $800.00K derived: sum of 2 quarters · filed 2025-11-04 | $800.00K 10-Q · filed 2025-11-04 | $800.00K derived: sum of 4 quarters · filed 2025-11-04 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-08-07 | $0.00 derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2025-05-06 | $0.00 derived: sum of 3 quarters · filed 2025-05-06 | -$300.00K derived: sum of 4 quarters · filed 2025-05-06 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | -$300.00K derived: sum of 3 quarters · filed 2025-02-27 | -$300.00K 10-K · filed 2025-02-27 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | -$300.00K derived: sum of 2 quarters · filed 2024-11-07 | -$300.00K 10-Q · filed 2024-11-07 | $5.30M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$300.00K 10-Q · filed 2024-08-08 | -$300.00K 10-Q · filed 2024-08-08 | $5.30M derived: sum of 3 quarters · filed 2024-08-08 | $4.00M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-04-25 | $5.60M derived: sum of 2 quarters · filed 2024-04-25 | $4.30M derived: sum of 3 quarters · filed 2024-04-25 | $4.00M derived: sum of 4 quarters · filed 2024-04-25 | |
| 2022-12-31 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $4.30M derived: sum of 2 quarters · filed 2024-02-29 | $4.00M derived: sum of 3 quarters · filed 2024-02-29 | $4.00M 10-K · filed 2024-02-29 | |
| 2022-09-30 | -$1.30M 10-Q · filed 2023-10-26 | -$1.60M derived: sum of 2 quarters · filed 2023-10-26 | -$1.60M 10-Q · filed 2023-10-26 | ||
| 2022-06-30 | -$300.00K 10-Q · filed 2023-08-03 | -$400.00K 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$100.00K 10-Q · filed 2023-04-27 | ||||
| 2021-12-31 | $800.00K 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |